Enanta Pharmaceuticals (ENTA) Expected to Announce Quarterly Earnings on Monday

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) is anticipated to announce its Q2 2025 earnings results before the market opens on Monday, May 5th. Analysts expect Enanta Pharmaceuticals to post earnings of ($1.16) per share and revenue of $15.96 million for the quarter.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last posted its earnings results on Monday, February 10th. The biotechnology company reported ($1.05) earnings per share for the quarter, topping the consensus estimate of ($1.16) by $0.11. Enanta Pharmaceuticals had a negative net margin of 157.57% and a negative return on equity of 75.53%. On average, analysts expect Enanta Pharmaceuticals to post $-5 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Enanta Pharmaceuticals Trading Down 1.7 %

Shares of Enanta Pharmaceuticals stock traded down $0.10 during mid-day trading on Friday, reaching $5.95. 101,428 shares of the stock were exchanged, compared to its average volume of 287,070. Enanta Pharmaceuticals has a fifty-two week low of $4.09 and a fifty-two week high of $17.24. The company has a market cap of $126.93 million, a price-to-earnings ratio of -1.20 and a beta of 0.81. The firm has a 50-day simple moving average of $5.91 and a 200 day simple moving average of $7.10.

Wall Street Analyst Weigh In

ENTA has been the subject of a number of research analyst reports. HC Wainwright reiterated a "buy" rating and issued a $18.00 target price on shares of Enanta Pharmaceuticals in a research note on Tuesday, February 11th. JMP Securities reiterated a "market outperform" rating and issued a $21.00 price objective on shares of Enanta Pharmaceuticals in a research report on Tuesday, February 11th. Finally, StockNews.com upgraded Enanta Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Wednesday, February 19th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $17.25.

Insider Activity at Enanta Pharmaceuticals

In other news, CEO Jay R. Luly purchased 45,000 shares of the firm's stock in a transaction that occurred on Wednesday, February 12th. The shares were acquired at an average price of $5.69 per share, for a total transaction of $256,050.00. Following the completion of the acquisition, the chief executive officer now directly owns 846,638 shares in the company, valued at approximately $4,817,370.22. The trade was a 5.61 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 13.89% of the stock is currently owned by company insiders.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.